Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant gemcitabine versus perioperative FOLFIRINOX in resectable pancreatic cancer
2013-003972-11Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in pancreatic adenocarcinoma (PDAC) comparing Adjuvant gemcitabine with Neoadjuvant + adjuvant FOLFIRINOX (2 arms). Primary endpoint: median overall survival. Started Feb 2014; status: completed.
02
Drugs
FOLFIRINOXgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2013-003972-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003972-11.